173 related articles for article (PubMed ID: 30514792)
1. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model.
Lee J; Kang TH; Yoo W; Choi H; Jo S; Kong K; Lee SR; Kim SU; Kim JS; Cho D; Kim J; Kim JY; Kwon ES; Kim S
Cancer Immunol Res; 2019 Feb; 7(2):219-229. PubMed ID: 30514792
[TBL] [Abstract][Full Text] [Related]
2. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
[TBL] [Abstract][Full Text] [Related]
3. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E; Kremer V; Childs R; Lundqvist A
Cancer Immunol Immunother; 2015 Feb; 64(2):225-35. PubMed ID: 25344904
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
5. Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of
Xia N; Haopeng P; Gong JU; Lu J; Chen Z; Zheng Y; Wang Z; Sun YU; Yang Z; Hoffman RM; Liu F
Anticancer Res; 2019 Nov; 39(11):5919-5925. PubMed ID: 31704816
[TBL] [Abstract][Full Text] [Related]
6. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
7. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.
Jewett A; Kos J; Fong Y; Ko MW; Safaei T; Perišić Nanut M; Kaur K
Semin Cancer Biol; 2018 Dec; 53():178-188. PubMed ID: 30081230
[TBL] [Abstract][Full Text] [Related]
8. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
Immunol Lett; 2017 Jun; 186():20-27. PubMed ID: 28392199
[TBL] [Abstract][Full Text] [Related]
9. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
10. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma.
Yang C; Cheng H; Zhang Y; Fan K; Luo G; Fan Z; Huang Q; Lu Y; Jin K; Wang Z; Yu X; Liu C
Cancer Immunol Immunother; 2018 Dec; 67(12):1815-1823. PubMed ID: 30167864
[TBL] [Abstract][Full Text] [Related]
11. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
12. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line.
Korbelik M; Sun J
Int J Cancer; 2001 Jul; 93(2):269-74. PubMed ID: 11410876
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
15. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
Kiany S; Gordon N
Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
[TBL] [Abstract][Full Text] [Related]
16. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
17. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells.
Stangl S; Wortmann A; Guertler U; Multhoff G
J Immunol; 2006 May; 176(10):6270-6. PubMed ID: 16670338
[TBL] [Abstract][Full Text] [Related]
18. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract][Full Text] [Related]
19. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.
Schwaiger T; Knittler MR; Grund C; Roemer-Oberdoerfer A; Kapp JF; Lerch MM; Mettenleiter TC; Mayerle J; Blohm U
Int J Cancer; 2017 Dec; 141(12):2505-2516. PubMed ID: 28857157
[TBL] [Abstract][Full Text] [Related]
20. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
